Random Clinical Pearls CPJE Exam Review 2024/2025 A+ Graded
Random Clinical Pearls CPJE Exam Review 2024/2025 A+ Graded Anakinra (Kineret) dosing freq - ANS-Once daily SQ IL-1 receptor antagonist, Biological DMARDs For: RA Etanercept (Enbrel) dosing freq - ANS-Once or twice weekly Bio DMARD Adalimumab (Humira) dosing freq - ANS-once weekly or every 2 weeks SQ Golimumab (Simponi) dosing freq - ANS-once monthly SQ Tocilizumab (Actemra) - ANS-once weekly or every 2 weeks SQ Hydroxychloroquine advantage vs caution - ANS-advantage: lack of hepatic or renal toxicity & lack of myelosuppression caution: may cause vision change or hearing change Leflunomide (Arava) advantage vs caution - ANS-advantage: can be removed by cholesteyramine or activated charcoal caution: Preg cat X and hepatotoxic Continues...
Geschreven voor
- Instelling
- Random Clinical Pearls CPJE
- Vak
- Random Clinical Pearls CPJE
Documentinformatie
- Geüpload op
- 11 oktober 2024
- Aantal pagina's
- 3
- Geschreven in
- 2024/2025
- Type
- Tentamen (uitwerkingen)
- Bevat
- Vragen en antwoorden
Onderwerpen
-
2024
-
2025
-
a graded
-
random clinical pearls cpje
-
random clinical pearls cpje exam review
-
anakinra kineret dosing freq
-
etanercept enbrel dosing freq
-
adalimumab humira dosing freq
Ook beschikbaar in voordeelbundel
